Literature DB >> 31895445

Translating the Secondary Prevention Therapeutic Boom Into Action.

Michael G Nanna1, Eric D Peterson1.   

Abstract

Entities:  

Year:  2020        PMID： 31895445      PMCID： PMC7329577          DOI： 10.1001/jamacardio.2019.4959

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  7 in total

1.  Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial.

Authors:  Tracy Y Wang; Lisa A Kaltenbach; Christopher P Cannon; Gregg C Fonarow; Niteesh K Choudhry; Timothy D Henry; David J Cohen; Durgesh Bhandary; Naeem D Khan; Kevin J Anstrom; Eric D Peterson
Journal:  JAMA       Date:  2019-01-01       Impact factor: 56.272

2.  Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease.

Authors:  Suzanne V Arnold; James A de Lemos; Robert S Rosenson; Christie M Ballantyne; Yuyin Liu; Katherine E Mues; Shushama Alam; Mary Elliott-Davey; Deepak L Bhatt; Christopher P Cannon; Mikhail Kosiborod
Journal:  Circulation       Date:  2019-06-07       Impact factor: 29.690

3.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis.

Authors:  Deepak L Bhatt; Kim A Eagle; E Magnus Ohman; Alan T Hirsch; Shinya Goto; Elizabeth M Mahoney; Peter W F Wilson; Mark J Alberts; Ralph D'Agostino; Chiau-Suong Liau; Jean-Louis Mas; Joachim Röther; Sidney C Smith; Geneviève Salette; Charles F Contant; Joseph M Massaro; Ph Gabriel Steg
Journal:  JAMA       Date:  2010-08-30       Impact factor: 56.272

4.  Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.

Authors:  Dean G Karalis; Usha G Mallya; Ameen F Ghannam; Joseph Elassal; Rishab Gupta; Susan H Boklage
Journal:  Am J Cardiol       Date:  2018-02-12       Impact factor: 2.778

5.  Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention.

Authors:  Martin Bødtker Mortensen; Michael Joseph Blaha; Børge Grønne Nordestgaard
Journal:  JAMA Cardiol       Date:  2020-02-01       Impact factor: 14.676

6.  Medical Marketing in the United States, 1997-2016.

Authors:  Lisa M Schwartz; Steven Woloshin
Journal:  JAMA       Date:  2019-01-01       Impact factor: 56.272

Review 7.  Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: the Global Burden of Disease 2010 study.

Authors:  Andrew E Moran; Mohammad H Forouzanfar; Gregory A Roth; George A Mensah; Majid Ezzati; Christopher J L Murray; Mohsen Naghavi
Journal:  Circulation       Date:  2014-02-26       Impact factor: 29.690
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.